Jones Trading Upgrades Editas Medicine (EDIT) to Buy, 'Potentially Best-in-Class Preclinical Data'
Tweet Send to a Friend
(Updated - March 10, 2026 10:19 AM EDT)
Jones Trading analyst Soumit Roy upgraded Editas Medicine (NASDAQ: EDIT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jones Trading analyst Soumit Roy upgraded Editas Medicine (NASDAQ: EDIT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
